Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

NCT01520103 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

139

Enrollment

OTHER

Sponsor class

Conditions

Her2-negative Metastatic Breast Cancer
Her2-negative Locally Advanced Breast Cancer

Interventions

DRUG: Vinorebine, Everolimus
DRUG: Vinorelbine

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]
[object Object]